Danish biotech Genmab has seen its shares double in three months after a string of major cancer drug trial successes, giving fresh momentum to its push to take greater control of the medicines it develops and sells. Shares in the roughly $35 billion company surged 48% last week, including a 29% jump in a single session after strong results for petosemtamab, its experimental head and neck cancer treatment. The announcement marked Genmab's third successful Phase 3 trial in October, following positive results for treatments targeting ovarian cancer and lymphoma. After nearly three decades spent building Genmab into one of Europe's prominent biotechnology companies, CEO Jan van de Winkel told CNBC on Friday the breakthroughs marked "a completely new era.
Головну думку ми показуємо публічно. Створіть безкоштовний акаунт, щоб читати повну статтю, зберігати її, обговорювати та поєднувати з ринковим і OSINT-контекстом.